Update From Seattle 2017

Update From Seattle 2017 (cont)

HIV Treatment

Dual ART – DTG + RPV SWORD-1 and SWORD-2

Dual ART – DTG + RPV SWORD-1 and SWORD-2 (cont)

Dual ART – CAB + RPV LATTE Wk 144 Results

Dual ART – CAB + RPV LATTE Wk 144 Results (cont)

Dual ART – CAB + RPV LATTE Wk 144 Results (cont)

Initial ART With TAF vs TDF Wk 144 Follow-Up

Dual ART LAMIDOL Study (ANRS 167)

Investigational Agent – Bictegravir Phase 2 Study Results

Investigational Agent – Doravirine DRIVE Study – Wk 48 Results

Investigational Agent – Doravirine DRIVE Study – Wk 48 Results (cont)

Investigational Agent – Doravirine DRIVE Study – Wk 48 Results (cont)

Investigational Agent – Capsid Inhibitor GS-CA1

Additional Investigational Agents Phase 1 or Phase 2

Comorbidities and Aging

Unrestricted Access of DAA Agents Rapid Uptake in Patients With HIV/HCV Coinfection

DAA Agents Treatment as Prevention in MSM?

Risk of HCC in Patients With HIV/HCV Coinfection After SVR (HCV) GEHEP-002 Cohort

Risk of HCC in Patients With HIV/HCV Coinfection After SVR GEHEP-002 Cohort (cont)

Risk of HCC in Patients With HIV/HCV Coinfection After SVR GEHEP-002 Cohort (cont)

Hepatic Steatosis The STERAL Study

Hepatic Steatosis The STERAL Study (cont) – Wk 48 Results

BMI and Risk for SNAEs

BMI and Risk for SNAEs (cont)

Aging and Frailty The ALIVE Cohort

Aging and Frailty The ALIVE Cohort (cont)

Summary and Clinical Implications

Abbreviations

Abbreviations (cont)

Abbreviations (cont)